Determinants of the variability of left ventricular hypertrophy in patients with hypertrophic cardiomyopathy  by Kelsey, Winifred et al.
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wevetorm to accurately match the aortic wevetorm (Figure), and (it) pral0ad 
reduction achieved with phase Iot Valsalva maneuver (VM). In 10 normal 
healthy male subjects aged 34.7 +1- 5.8 (mean ~ SD), we Studied the repro- 
dudbllify of this system dudng four conseouthm preload rsdu~on runs. 
Results: VM reduces preload (end diastolic area: from 12.7 4.1.8 to 10.3 
:E 1.6 ~n~, p < 0,001, ANOVA), end systolic pressure (from 99.1 d~ 14.8 
to 89,7 d: 17.5 mmHg, p < 0.001) and LV work (stroke force: from 6-53.0 
4+ 165.3 to 454.6:1:117.0 mmHg,cm ~, p < 0,001)+ Of the two measures of 
LV Systolic function, the end systolic pressure-area relationship was highly 
nonlinear (in: 0.54 4. 0.2B'vs 0.87 ± 0.17, p < 0.001) and exhibited higher 
variability (SD/mean) than the stroke force-and diastolic area ral~onship for 
both slope (0.31 vs 0+11 ) and intercept (0.46 vs O.22).condusion: This totally 
norHnvasive method should be useful in assessing the Systolic LV function 
repeatedly in clinical settings. 
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Prelcad-AdJuMed Maximal Power U .singl 
- Echocerdiogmphic Automated Eomer  0etection to 
As~meaz Left Yentd©mar i 'unet lon 
Christine M. Mahler, William E. Katz, Sdnivas Murati, Mare D. Feldman, 
John Gorcoan IlL University of Pit,burgh, PittsDurgh, PA 
Prsioad~edjusted maximal power (PAMP) has recently been validated as a 
load insensitive measure of LV function. The objective was to estimate PAMP 
in at# with severe congestive hqart failure {CHF) and normal subjesls using 
automated ectlocardmgraphic LV volume areo s~mu;tarteous i~),~inv~uive ar- 
terial pressure. Ten CHF pts, aged 45 a- 10 yrs, (LVEF 2t =E 6%) and 10 
normal subjects, aged 32 4- 3 yrs, (LVEF 56 ~ 5%) were stUclled at base- 
line and with 10/~g/kg/min dobutamtne infusion. LV volume by 4-chamber 
view Simpaon's rule and artsdal pressure by a finger cuff photoplethysme- 
graph were acquired on-lice. The first derivative of LV volume was multiplied 
by pressure to estimate maximal LV power, then adjusted by dividing by 
end.diastslic volume squsmd. Volume and power examples are shown. 
Heart FnihJm Patient Normal Sub|act 
[q~selLa. ± ,  I_D_o _b~_ a=min.e_ J I.B as . . . . . . .  
2.S~ ~s~,~ ~ie~ . . . . . .  2.S SeC 
Baseline PAMP was 0,84 4. 0.63 Wlml :~ in CHF pts vs, 4,18 4.1.64 W/ml ~ 
in normals (p < 0.001). PAMP Increased with dobutamtne to 1.55 d: t.56" in 
CHF pts and 8.39 ptusmn; 3,73 = W/mF in normads (+p < 0.05 vs. baseline 
& normal, +p < 0.001 vs. baseline), PAMP using e~ho automated bOKior 
detection has potential to assess LV function. 
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Echocerdlogmphlc Assessment of Left Ventflcular 
. . . . . . .  systol ic  Fun~/on In Transgenlc Mice With Cardla¢~ 
~pecif ic over-P.~pmeadon of Phosphole~mban 
Bdan D, Holt, Zia U, Khan, Nancy Ball, Vivak J+ Kedambl, Evangelia 
G, Kranlas, Richard A, Welsh. University of Cincinnati, Cincinnati, OH 
In v/fro studies have demonstrated that dephosphorylaled phespholam- 
ban (PLB) Is an Inhibitor of the cardiac sarcoplasmlo retlculum ($R) e:al. 
¢lum ATPase (Ca ~+ ATPase), and that phusphorylati0n of this 10retain by 
cat~holamin~mediated stimulation of cyclic AMP-dependent protein klnase 
relieves this inhibition and facilitates reuptake of calcium by the SR. TO de- 
termina the effects of PLB on in vivo LV systolic function and assess the 
stolchlomeW between PLB and the SR Ca 2+ ATPase, 15 transgenic mice 
with cardiac spadfk: overexpresalon of phcapholamban (PLBOE) driven by 
the =+myosin heavy chain promoter, and 16 wifdtypa age.matched con- 
trois iCON) were studied under light anesthesia with 2D-directed M-mode 
and Doppler using a 9 MHz Imagtng and 5-7,5 MHz Doppler transducer 
(Interspe¢-ATL GX 200). LV shortening fraction (SF), heart rate-corrected 
velocity of clrcumferentiad shortening (Vcf~), peak aortic velocity (AOV) and 
mean aortic acceleration (Ac~) were compared at basallns (BASE) anti after 
intraperitsneal isopreterenol (leO) injection (2 p.g/gm): 
CON PLBOE 
BASE ISO BASE fSO 
HR (bl~n) 292:1=87 452+69* 280±98 431 ,++95 ~ 
SF(%) 44+5 68+5+ 35±61" 64:~4, 
Vcfe (clrP.Js) 6.2-~ 1.9 11,5 =t: 2.1" 4.2 :E 1.01' 10.4:E2.1" 
AoV tom/s) 71.3+12,9 88,5+ I?.P 66,fi:E S,4 92.5 =E 13.0+ 
ACe (m/s ~) 3.74- t ,S 6.0 4- 2.2" 2.9 :E 0.9 6+5 :E 1.64 
Data are mean ± SO; "p < 0.05 vs. BASE, 1" p < 0.05 vS+ CON 
Wdh ISO, the percent increase in SF, Vcf~ and mean acceleration were 
signiticardly greater in PLBOE than CON. We conclude that ovs=exprs~sion 
of phospholamban: 1) decreases basal LV systolic function, indicating that 
a fraction of the samoplasmtc reticulum Ca ~+ ATPase in wtldtype mice is 
not under regulation by phospholamban, and 2) enhances inotropi¢, but not 
chmnotropic sensitivity to ,8 adrenergio stimulation. 
10:45 
Rapid Coord ina~ Up regulstIpn of Nuclear and 
- - Mitocnonddal  Gene ~xpresslon In Response to  
Cardiac Load 
Gregg 1". Schuyler, Tarrenco X. O'Bfien, John D. Rozioh, Robert L. Kent, 
Diane E. McDermott, Paul J. McDermott, George Cooper IV, Donald 
R. Mesick. Gazes Cardiac. R~rch  Instit~e and Mad. Univ. of 8C, 
Cherteston, 8C 29425 
To identify important ranscripts uprngulatsd during acute dght ventricutar 
(RV) pressure ovedoad in the adult cat, differential hybridization was uti. 
lized. A modified Swan+Ganz catheter was used to partially obstruct he RV 
outflow, under flourescopy, creating a RV pressure overload. The balloon 
was positioned such that the systemic preSSure was unchanged resulting 
in a same animal conlml normally loaded left ventricle (LV), cDl~e, libraries 
construcod from RV end LV were differentially hybrit~ized to sets¢~ ~o';~oloneo 
present in the RV but ab~nt in the LV. One upregulated done, confirmed 
by Northern blot hyioddizatton, corresponded to the mitochor~ldal F1 AT- 
Pase Subunit FOe whose sequence is encoded in the mifoohooddon (Mt). 
This upregulation was also demonstrated in related Mt encoded tmnomlpt~, 
cytochreme b and cyteshmme oxldase subunit II. To demonstrate a ooardi- 
nate upmgulation of mifochonddal respiratory proteins whlch am encoded in 
the nucleus, the levels of transcripts of cytoohmme C, cytochreme oxidase 
subunit IV, and mitesbanddal RNA processing RNA were analyzed. Again a 
rapid upregulation in response to acute hemodynamto load was observed. 
This in v/ve effect was then tested in vitro In Isolated neonatal rat ventdcu+ 
lar cardiowtas treated with phenylephdne (PE) stimulation. Similar changes 
in the mRNA levels were seen after 1-2 hr. At the protein level, Western 
analysis of cytuchrome c showed a algniflcent increase within 3 days of PE 
stimulation. Addifionadly, to correlate the neonatal cell studies with adult cellS, 
feline adult cardleoytas were stretched for 1 hour on a deformable mem- 
brane, with similar results. These studies suggest both in rive and in vitro, 
a cardias regulalopj mechanism that responds to hyperlrophic stimuli with a 
rapid coordinate upregulatien of nuclear and mitochondrial genes encoding 
the oxidative phesphorylation components, 
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~ De~rmlnan~ o~ the Vadabll!ty of Left VentdcuIar 
Hypertrophy in Patients With Hypertrophic 
Cardiomyopsthy 
Winifred Kelsey, Antoine Abchee, Marcel Leohin, Robert Roberts, All 
J. Marian, Bay~or College Of Medicine, Houston, TX 
The hallmark of phenotypic expression of Hypertrophic ¢ardiomyopathy 
(HCM) is left ventdcular hypertrophy (LVH). However, the magnitude and 
extent of LVH in patients with HCM, even in those with the same underlying 
mutation, are variable, A number of gen~c end environmental factors are 
likely to Influence the phenotypic expression of LVH in patients with HCM. 
We have previously shown that ACE gsnolypos account for 5-10°/= of the 
variability of the extent and magnitude of LVH in patients with HCM. In this 
study we determined the influence of gender, age, heigM, weight, bo(ff mass 
index, angiotensinngen (AGT) ganutypes T174M, and M295T, angiotensin II
receptor la (ATRla) genctypes on left ventdcular mass Index (LVMI) cal¢u. 
lated by area.lenghth method, and extent of hypem~hy determined using 
a semlquantitative point score (Score 1,.+t0). Multiple regression analysis 
showed that only geodar and ACE ge~~otypas were correlated with LVMI 
and extent of LVH. LVMI was greater in male (n = 61) than in female (w.47) 
patients with HCM (145.96 4. 34 vs. 129.42 :b 33, p = 0.013). Similarly, made 
patients had mote extensive hypertrophy than female pa~ents (seem 6A 4. 
2.2 vs. 5.3 + 1.9, p w= 0.029). Gender accounted for 4,8% and 5.4% of the 
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va~ Of Ihe LVMI ar~l extent of LVH in ix~e~s Mth HCM. "1~,  
~.~-~- ;~1 ACE genotyp~  f~r 5.4, and 10o1% of lhe v 'ad~ of 
LVMI m-d extent Of hypertrophy. Neither AGT genotYpe~ (T174M asd M~51") 
nor AT IIFla g~otypes had any in l lu~ on LVMI ;~nd s~me of Izypeflrol~. 
TII~, gender and AGE genotyp~ account f~' a frax~on of tl'~ v'miabTdy Of 
tl~ i~ l~ io  ~ of LVH in pafle~ with HOM. The greatef mag- 
dtude Of ~ in male ~ r~s ~-,;~-.)s1~ ~ Previous 
repolts have Shown !~n male patierds w~th HCM m v,u-~ I~  ~o be victim 
Of s~, .~ 0argo e~th t~_.n fen'k~eS. Our resu~ ~ that g',e repo~ 
Idgher Inc~ler,~ of sud~ can~ de~ In male pUlents Is due In pan ~ two 
gen~ f'a~m: male gender and ACE genolype. Mulati~ causi~ HCM 
~ wi~ ~ e~t~mive ,~-~:.~lar hyp~rophy when it occu~ 
in t~  male as ~ ~o female gender. The ,~,-,,,~,~m of mate gentler 
and b'le ACE genotype DO mw pm~;p~ to a hi~l~e~ inckk~ of ~mdden 
car~ de~h In HCM. 
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Tev~ Aoyagt, Ya~-unob~ Hirata, 8htn-ichi Momomura, ~ Pedasamy. 
The ~ ~ ret~utum C.~+Al-Pase (SERCA2) ~ and 
mRNA were known to be ~- ,~;ed  in mm~y I~l~ogical ~ua~ions tch 
s ~  of SERC, A2 are yet to be i ~  espe~ in in vivo se1~ 
ir~o a felt ven'idcular pex of ~'~It rat basils. T ~  leve~ of SERCA2 
was evat,ated by L,c assay in myocar~ Um~e ~ .  Trars~ Of- 
~-y  vm e~n~d by t~ expess~ of ~n j~ed ~o,s t~y a~e 
p.gal gene. First. we ir~e~ed the (:onstnx~ *1110Lu~ conr~¢~ of -1110t~ 
upstream region of SERCA2 promoter and Luc reporter. ~ Luc a~ 
~vitywas 256 :E 119~. 44 ~- 26~,40 ~:8',31 :E 15", 13 ~ P; time~ l~her 
~ ~  at I, 2. 3. 4 and 5~,~ ~e~ me ~N, ,  ~ ,m~y.  
' I~  mqxesslon of ~oas'tru~ wlt~ ~ns  in 6ERCA~ ~ -.6~Luc, 
~Luc  -~TLuc, -7'~.ue were examined or~ week a~er the ~ Luc 
ac~y v~e Sl ..'- . * ,  ~,4 -~ s~, 2o .  ~, a.d 0.OS .-'- 0.0t§ fords o~ maz ~ 
-11101.~injected rats, ~ .  tn compensa~ 10msste~e-ovedo~ hy- 
per t~ induced by g~e DOCA-s~t method, my~ar~ exp , -~ ~f t~ 
.1110t~ constnx:t was siam'far ('/5.2%) to 8~at in Sham controls at o~e week. 
In co~'~ast, a severe ~ m~,~ ban~ (mean pressure grad~e~ 88 
rr~lg , .~  a ,esme~ mortarny: 40%) ~ ~ ,;e~,~ed ~, -~ 
(35.7%* of Slzan controls) at one week. Thus, the ,~x~,st~n of SERCA2 
pramwr inJec~ in vivo was ~ in compensated ~ .  ~ 
de~ irl sevem ~ ~-~:~e-ovedoa~ (§ p < 0.05,'p < 
0.0;) 
11.'30 
Sedal EchocardlograpMc ~ of Left 
Ventrieulsr Funetlon and Ge~e AnMyMs of 
~ Prollein and Cc~agen A f t~ ~ i a l  
Aklh~sa ~ i ,  Minoru Yoshlyama, Iku Toda, l<~mame 
Masakazu Terdgakl. Kazullide Takeu~, Jyl~Ud YoShikawa. F~t 
The f :~  Of this study were to assess Ihe elfe~t of ~ n  II lype 
1 recepto~ antagonist (TCV.116; t0 n~kO/day) on left verdficul~" func~on 
by us~g ~ and t~ anatyz~ gene ~. , -~~ of contract, e 
prote~ asd ~ogage~ t,mo~," an~- myocan~ ~ Myo~,d~ Infam- 
tion was made by llgal}on of comna~ arlely In Wistar rats and TG'V+t16 was 
admlnisten~ after su~geeJo On 1, 2 and 3 weeks after ~ krdan:~'0a. 
left ventdcu~ geomeW was measured and mRNAs In canJiac I~sue were 
LV er,~amr¢ ~ (LVOd) and ~ sho~m~ (FS) 
on I week were 9.1 ~ 0.6 mm al'¢116 ~ 4%, n~ec6~/ ,  and LVDd on 3 
weeks IncreaSed ~ 11.1:1:0.8 (p < 0.0b') ard F~ d~n~U~ to 11.5 • 5% 
(p < 0,01). TCV-116 IXeV~-i;~ an increase of LVEDV (92 ~- 0.5 ram; p < 
0.01) and ~ FS (17 :t= 5%; p < 0,01) on 3 wee~ ~le leR verdlk:ular 
u~t  ~,,If~,~y ~ ~ 3 we~s ~ n~,~'~,a~ infar~on (2.41 • 
0.0~ ~) .  ~h w~ ~ by T~Vm6 ~ ~ ± 0.~ g~g;P 
um~ I ~  (ANP), ~ growth f"dCt~ (TGF)-~I, collage~ types I, 
lit, IV, and matrf~ n ~  (MMP).2 in 1he ~ lefl venblc- 
ular ~ ~ by 3.0-, 6.7-, 1.6-, 7.9-, 4.t-, 2.t~. stud 1A-fold on 
1 waek, respectiv~ (p < 0.01). a-~o~Sal ac~in mRNA i r~,~ l  on 3 wee ks 
by ~.gjou (p < o.01), TCV-I~S si~i~ar~y ~ ma im~a~ 0ene 
expmsdons of p-MHC, ~-skeletal c~n asd ANR On tile oltter Iland, TGF-pl, 
6br0rmC~, CxzgaQen I, III, IV, and MMP-2 mRNAs In the ischee~ region ~g- 
nificangy increased by 6.6,12.0, 26.2., 12.7. 5.6,, and P..2~old, respe~ively. 
TCV-t16 o~d not affect TGF-pl, fi~mec~, and collagen I, HI, iV h~RNAs 
in ischen~ a.,xl noetschemlc reg~ocs However, it increased MMP-2 mRNAs 
on 1 week ~ both ~,gions. In conduston, TCV-116 prevented ~ 
file change of the ~-~as  of cordractile Ixotetn. TCV-116 acceleva~ 
g',e gene expmsslon Of MMP-~ which may be con~ted to prevent can~ 
fiixos~ 
11:45 
Masa~ Maed~ fJ~ma Hok~r, l~an Lowas, Ro,e~ D. l~s. 0 ~  o~ 
VAMecrc~C.emertnOUnimrs~o~Hea l th~ 
Cente~, Oenv~, CO. 
Melavtn~n is a card~ a~d smooth muscle spt~ i~ofonn of ~e cy. 
toskel~ ~tein vfnC~, wWch come~ ac~n f~urents to ttra ~,,-~/~,;.,,a 
in the cell. Metavincu~ c~ab~ a ~l a~.-,-~.-~ ~ exon ~-~ an 
~ ' ~  ~ ~r~,  ~dd~ near the C t~n~us o~ vinm~, and i~ Ioc~ to 
the ~ ~cs  and ~ of ~u~as mus~ an~ ~ v ~  ~s- 
so~a~ I~1~ tn smooth rnusde. ~n 1ms n~o~t ~ d~r~ a intent w~h 
kr, opae~c ~,a~e~ r~omyopa~ OOc) and ee~ence o~ ~=;,~c metav~ 
• ~,,n. Polyneraas cl~n rea~o~ (PCR) anatysts (~m~r, sa'-a~ a,~e~e of 
the ~ mRNA ~ isofOnn tn ca~c tissue from a s.qect 
in bo~ our 10C su~ ;~d co~I~o~, PCR of ~non~ DNA ~m the t~ 
sut~ demonslnm~ g~e pn~m(:e of an b~ct ~.~;~vlno~ exon~ West- 
ern bk~ a.alysls dem.s~ed abse~e of me~avlnct~ but r~ vd~rm in 
t~ue homogem~ from ~e IOC hea~ ~ of ~a~ v~t~n 
,~,-,~,~;.-~,~  inler~_.~ ~_~ disc s '~cm~ in our subi~ 
pared ~) thoas ~ ~ cor~ The ~ defi~ncy Zn 
t~s sul~ect e~as not amear to m se~- ,~y to a ~ process m 
~ed heart is~e. Tw~ty ek~t human he~'t ~ were an~yze~ 
fnclud~ mree ~;~ corroo~ rr~e ~ ~ ,  one X ~  
cass~mpamy, and n~ne~m s~s ,~th  k~c  d~ can~o~yo~ 
my. ~ ~ was orgy de.:ted in the one su~je~ des~bed 
In ~ re l~ C ,~ ~ of v i~  a~xl othe~ o m ~  pro~ 
asm:~eed w~h 10om the Z ~re~ (=-ace~), and the membm.e (d)~~.'~n) 
were nmmaL These results denM-., ; ,~ a deficlen~ f ~ mRNA 
and l~tein M a su l~ v~1 di~a~?~ c a n ~ ,  i ~  due to a 
defe~ in mRNA a]~-r~ve 
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Does ACE Genoq~3e influence the Oe~ent  of 
Left Ven~iculmr ~ in Untmm~l 
Jaw~ Ma~ Kevin P. J. O'Kase, Man~ Shahi, Mick/k. (~kor, ~ 
A. Johnszone, N~ FL Poefler, Pe~r S. Sew~, Rodrey A. Fo~. O;~d 
J. WOf~ S~non A, MeG. Thorn. St. Mary's Hospt~ ~ and Western 
The presenoe of LVH IXedCs an i~reased ~ ard mortat~ in P~ents 
with hyp,~,~,~,k,~;~',~ The ACE gene has been fouml ~ have 3 ~-,,~-ypes and 
the O all~e has Ixmn fom¢ to be ~ wi~ a r~.;;~- of caNtac 
~sease¢ Our hypolheds was that me ircrmsed pU,~v,~ ACE leve~ Pmse.t 
tn the DO genotype group m~ result in as increased tendmcy eo develop LVH 
either Gqm:~ or Incf~ectly ~a 1he ~ects of BI:'. We haw a,~,~;ed this issue 
Each genofype ~mu4p had similar ma~efleenmle ~ (1110/6, ID ~10,  DD 
14/7), agas (1147 :b 3, ID 48:1: 3, DD 47 :E 3 yearn), BP (11163 :b 4196 :E 
~. IO 167 ~ 4 /~I  ~ 2, DO 161 ::E 4 / 96 ~ 3 mmHo) and caxrlta~ stnx;tmal 
and ltjncfJonal pararrmtm's [~ft ~ mass ittdex ~VMI), It 136 -t" 9, ID 
132 ;:1: 7, DO 131 + 8 g~Z; E/A raZio, tl 1.07 ~ 0.t, IO 1,07 • 0,09, DD 
1.03 ::E 0.07; ISORdtlmic ~ t~ II 105:1: 7, IO IQ~I • 4, OD 97 :E 6 
ms]. In each group them m.s a significant relatiomh~ betwe~ syslolic BP 
and LVM] (II r :  0,SS, p ,= 0.02,10 r = 0.40. p = 0,02, DD r ~ OAg. P = 0. 0~ 
The ~emnce in ~tese corm~im~ tx~veen the 3 ~ gmq~s was not 
TNs woldd so~ 1hat AGE ge~ does not exe~ a large influence on 
